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ABSTRACT
A growing body of evidence suggests an essential role
of the heterodimeric cytokine, IL-27, for regulating im-
munity. IL-27 is composed of two subunits (p28 and
EBI3) and is classified as a member of the IL-12 family
of cytokines. APCs have been recognized as a major
cellular source of IL-27 following activation with micro-
bial products or IFNs (types I and II). In this review, we
describe the current knowledge of the implications of
IL-27 during the pathogenesis of infectious and autoim-
mune diseases. Experimental studies have used genet-
ically targeted IL-27RA/ mice, EBI3/ mice, and
p28/ mice or involved study designs with administra-
tion of bioengineered IL-27/IL-27RA homologs.
Whereas many reports have described that IL-27 sup-
presses inflammation, we also review the current litera-
ture, suggesting promotion of inflammation by IL-27 in
some settings. Recent advances have also been made
in understanding the cross-talk of cleavage products of
the complement system with IL-27-mediated immune
responses. Additional data on IL-27 have been ob-
tained recently by observational studies in human pa-
tients with acute and chronic inflammatory diseases.
Collectively, the findings from the past decade identify
IL-27 as a critical immunoregulatory cytokine, espe-
cially for T cells, whereas some controversy is fueled by
results challenging the view of IL-27 as a classical si-
lencer of inflammation. J. Leukoc. Biol. 94: 1159–1165;
2013.
IL-27 was first described by Pflanz and colleagues [1] in 2002
as a cytokine with activity on T cells. Notably, the discovery of
IL-27 may have been complicated by the fact that the different
protein chains of IL-27 are encoded on independent gene
loci. Over the past decade, scientific efforts have aimed to ana-
lyze structure, signaling, and biological effects of IL-27. De-
spite accumulating literature on IL-27, several aspects of this
cytokine remain enigmatic. In this review, we will provide a
perspective of the current knowledge of IL-27 functions and
implications during autoimmune and infectious diseases. We
present C5a as a selective regulator of IL-27 gene expression.
Furthermore, we dissect the available literature, classifying
IL-27 as a proinflammatory or anti-inflammatory factor during
acute and chronic models of inflammation.
STRUCTURE OF IL-27
The heterodimeric, glycosylated protein IL-27 is assembled by
the subunits p28 (also known as IL-27p28, IL-27A, IL-30) and
EBI3 [1]. EBI3 is a 229-aa protein (mouse: 228 aa) encoded
on human chromosome 19 (mouse: chromosome 17). The
subunit p28 consists of 243 aa (mouse: 234 aa) and is located
on human chromosome 16 (mouse: chromosome 7). Whereas
the predicted structure of p28 is a four-helical cytokine, EBI3
is considered to be a soluble receptor [2]. The predicted in-
terface of p28/EBI3 is composed of noncovalent bonds of dis-
tinct hydrophobic and polar properties involving specific
amino acid residues of p28 (Trp97) and EBI3 (Phe97, Asp210,
Glu159) [2]. IL-27 displays sequence homology with members
of the IL-6/IL-12 family of cytokines. Genes encoding for ho-
mologs of IL-27 subunits have been identified in nearly 20
mammalian species, whereas little information is available for
other vertebrates.
In humans and rodents, other binding partners for p28 or
EBI3 exist (Fig. 1). EBI3 can associate with the subunit p35
(IL-12A), resulting in the cytokine IL-35 [3]. In addition, p28
appears to have another binding partner, CLF-1 [4]. The exis-
tence and biological relevance of homodimers (EBI3/EBI3;
p28/p28) and isolated secreted subunits of p28 or EBI3 are
not entirely clear, but such molecules may act as natural antag-
onists of heterodimeric IL-27 [5].
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IL-27R AND SIGNALING
IL-27 binds to a heterodimeric receptor complex, which is
composed of a ligand-binding chain, IL-27RA (WSX-1, TCCR),
and an additional signal-transducing chain, gp130 [6, 7]. Of
note, IL-27RA includes a cytoplasmatic domain with Box 1 mo-
tif binding sites for JAK1/2, which contributes to signal trans-
duction of the IL-27RA/gp130 dimer [6]. The common gp130
chain is shared by several other receptors for signaling of cyto-
kines, such as IL-6, IL-11, and leukemia inhibitory factor [8].
The situation becomes even more complex with heterodimers
of CLF-1/p28 binding to a trimeric receptor complex com-
posed of IL-27RA/gp130/IL-6RA [9].
Whereas gp130 is found widely in various tissues, the expres-
sion of IL-27RA appears to be more restricted to immune
cells, such as T, B, NK, plasma, and possibly cells of the my-
eloid lineage [7, 10, 11]. However, IL-27RA may also be ex-
pressed on transformed, malignant, nonimmune cells [12].
IL-27, via IL-27RA/gp130, activates JAK and STAT1/STAT3.
STAT1 and STAT3 modulate the activity of downstream T cell
lineage-specific transcription factors, such as T-bet (Th1),
GATA-3 (Th2), and retinoic acid receptor-related orphan re-
ceptor t (Th17). In addition, IL-27 signaling activates p38
MAPK and recruits the transcription factors c-Maf and the
AhR [13, 14].
REGULATION OF IL-27 GENE
EXPRESSION BY MICROBIAL PRODUCTS
AND ENDOGENOUS FACTORS
IL-27 is expressed mainly by APCs (macrophages and DCs)
after encountering microbial products. Abundant quantities of
IL-27 are secreted after activation of PRRs, such as TLR3
(polyinosinic:polycytidylic acid), TLR4 (LPS), and in some re-
ports, TLR7 (loxoribine) and TLR9 (CpG) [15–17]. Irradiated
gram-negative bacteria (e.g., Escherichia coli) induced expres-
sion of p28 in human monocyte-derived DCs [18]. Similar re-
sults were obtained for IL-27 induction by viable Salmonella
enteritidis [19]. Production of IL-27 has been noted during vi-
ral, bacterial, protozoan, and fungal infections in vivo [17, 20–
22] (Fig. 2).
TLRs recruit the adaptor molecules MyD88 and TRIF for initia-
tion of downstream signaling cascades. After activation of TLR4
with LPS, MyD88 and TRIF are required for full activation of
IL-27 gene expression [23, 24]. Subsequently, transcription fac-
tors, such as NF-B (c-Rel), IRF-1, IRF-3, and IRF-9, bind to the
promoter region of p28 [23–25]. An important amplifying circuit
for IL-27 production has been identified as endogenous types I
and II IFNs [23–25]. IFNs may also be a relevant trigger to initi-
ate IL-27 production during autoimmune diseases.
Another pathway to activate IL-27 production in myeloid
cells is activation of the costimulatory molecule, 4-1BB
(CD137), a member of the TNFR family, using agonistic anti-
bodies [26].
Extracellular ATP, which is viewed as a “danger signal” fol-
lowing tissue injury, mediates suppression of p28 and less po-
tently of EBI3 [27]. These effects involve signaling via puriner-
gic (P2) receptors (e.g., P2Y11 receptor) [27]. In addition,
IL-27 appears to be silenced following activation of the com-
plement system.
IL-27 AND THE COMPLEMENT SYSTEM
The complement system is part of innate immune defenses
and is required for immediate clearance of pathogens [28,
29]. In addition, complement activation products, such as C3a,
C4a, and C5a, act as potent anaphylatoxins to orchestrate the
activation and chemotaxis of various immune cells [29]. Com-
plement cleavage products induce complex signaling cascades
to maintain immune surveillance and tissue homeostasis [28].
For instance, the classical receptor for C5a (C5aR) is ex-
pressed abundantly on PMN leukocytes and to a lesser extent,
on macrophages [15]. Ligation of C5a with C5aR suppresses
gene expression and release of p28 from F4/80 macrophages
[15, 30, 31]. Likewise, the C5a degradation product, C5adesArg,
has retained some functionality to antagonize p28 production
from macrophages, presumably with less potency than C5a
[15]. During endotoxic shock, higher amounts of p28 are gen-
erated in C5aR/ mice compared with WT mice, whereas
no such effects have been observed in mice deficient in the
second C5a receptor, C5L2 [15]. In cell culture experiments,
lower frequencies of F4/80p28 macrophages were ob-
served, when LPS (TLR4 activation) was combined with C5a
treatment. The inhibitory effects of C5a on p28 gene expres-
Figure 2. Regulation of IL-27 p28 gene expression by the complement
system in the context of infection. Viral infections activate the TLR3
pathway, whereas bacterial infections predominantly activate the TLR4
pathway. Simultaneous, complement activation results in generation of
the anaphylatoxin, C5a, which recruits PI3K-Akt for selective inhibition
of the TLR4 pathway to limit IL-27 production.
Figure 1. Subunits of IL-12 family members and their known associa-
tions as heterodimers. p35, IL-12A; p40, IL-12B.
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sion are linked to activation of PI3K/Akt signaling by C5a
[15]. An in vivo blockade of Akt, using the small molecule in-
hibitor, wortmannin, resulted in threefold higher plasma con-
centrations of p28 during endotoxic shock [15]. Interestingly,
suppression of IL-27 by C5a was specific when IL-27 was in-
duced via TLR4, whereas TLR3-induced IL-27 was unaffected
[15]. This demonstrates that the IL-27 appearance may be spe-
cifically regulated by C5a, depending on the context of bacte-
rial (TLR4) as opposed to viral (TLR3) infections (Fig. 2). In
the future, it may be important to evaluate to what extent
complement-driven regulation of IL-27-dependent immune
responses participates in development and progression of
chronic diseases and inflammatory clinical conditions.
ACTIVATION OF INFLAMMATION BY
IL-27
In first reports, IL-27 was described as promoting a rapid,
clonal expansion of naive CD4 T cells and triggering IFN-
production by CD4 T cells [1]. Since then, many investiga-
tions into the role of IL-27 in diseases have used IL-27RA/
mice (disruption of IL-27 signaling; Table 1). In a T cell-trans-
fer model of colitis, IL-27RA/ mice were protected from
colonic inflammation and weight loss [40]. Such mice showed
reduced frequencies of Foxp3 Tregs and reduced IFN- pro-
duction [40]. In another study, CD4CD45RB T cells from
IL-27RA/ mice failed to induce colitis in recombination-
activating gene/ recipient mice, but on the other side,
IL-27 was indispensable for prevention of colitis by Tregs [41].
Apparently, IL-27 confers long-term survival of T cells by
down-regulation of Fas ligand and up-regulation of antiapop-
totic caspase 8 homologue Fas-associated death domain-like
IL-1-converting enzyme-like inhibitory protein [41].
IL-27 was essential for production of IL-21 by Th follicular
cells, via STAT3, in germinal centers [42]. In IL-27RA/
mice, the production of high-affinity antibodies/autoantibod-
ies was reduced, resulting in diminished severity of glomerulo-
nephritis [42]. In proteoglycan-induced arthritis, IL-27RA/
mice were protected, including delayed onset and reduced
severity of disease, as documented by less cartilage destruction
compared with WT mice [35]. The diminished arthritis in IL-
27RA/ mice was associated with fewer IFN--producing T
cells and Th17 cells [35]. On the other hand, the implications
of IL-27 in arthritis are puzzling, given other reports that ad-
ministration of bioengineered EBI3-L-p28-Fc fusion protein
ameliorated joint inflammation in collagen-induced arthritis
(ref. [36]; also reviewed elsewhere in ref. [43]). EBI3/
mice were protected from Con A-induced T cell-dependent
hepatitis, a disease model associated with IFN- production,
along with pSTAT1 and T-bet activation [44]. STAT1 was re-
ported to mediate IL-27-induced NO production from perito-
neal-elicited macrophages [45].
It has been reported that in lung fibroblasts, IL-27 induces
the expression of CXCL10 (IFN--inducible protein 10) via
Table 1. Effects of IL-27 in Experimental Models of Disease
Disease model IL-27 strategy Major findings Ref.
EAE IL-27RA/ IL-27 suppressed development of Th17 cells. [32]
Toxoplasma gondii infection IL-27RA/ IL-27 antagonized Th17 cell functions during
neuroinflammation.
[33]
T. gondii infection IL-27RA/ Absence of IL-27 mediates lethal T cell-mediated
inflammatory disease; excessive production of
IFN-.
[21]
T. gondii infection IL-27RA/ IL-27 induced IL-10 in T cells via STAT3. [34]
Proteoglycan-induced arthritis IL-27RA/ IL-27 promoted severity of arthritis; induction of
Th1 response.
[35]
Collagen-induced arthritis EBI3-L-p28-Fc IL-27 attenuated histology scores and joint
inflammation; less proinflammatory cytokines.
[36]
Listeria monocytogenes IL-27RA/ IL-27 promoted IL-10 production; lower frequency
of IL-10 T cells in IL-27RA/ mice.
[37]
Trypanosoma cruzi infection IL-27RA/ IL-27 antagonized parasitemia, severe liver injury,
mortality, and proinflammatory cytokines (IL-6,
TNF-, IFN-).
[38]
Septic peritonitis IL-27RA-Fc soluble receptor There was an improved survival with blockade of
IL-27 during sepsis.
[20]
TNBS-induced colitis Single-chain human IL-27 IL-27 treatment improved disease scores and
inflammation in colon and LNs;
proinflammatory cytokines (IL-17) were
suppressed.
[39]
T cell-dependent colitis IL-27RA/ IL-27RA/ showed less weight loss and colonic
inflammation, including IFN- production;
more Foxp3 T cells.
[40]
N.A. p28-Transgenic mice There was overexpression of p28 (in T and B
cells), independent of EBI3; p28 antagonized
interaction of IL-6 with gp130.
[5]
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p38 MAPK and PI3K-Akt signaling pathways [46]. Proinflam-
matory CXCL10 plays an important role for chemoattraction
of activated T cells to sites of inflammation. CXCL10/
mice display impaired T cell responses, including proliferation
after antigen challenge, secretion of IFN-, and pathogen
clearance [47].
Finally, IL-27 promotes protective tumor surveillance against
endogenous murine tumors [48]. In settings of mammary car-
cinoma or fibrosarcoma, the development and tumor growth
in IL-27RA/ mice were accelerated, and IL-27RA/ mice
displayed a defective IFN- response and higher frequencies of
Tregs [48].
INHIBITION OF INFLAMMATION BY IL-27
Several reports have suggested that IL-27 may play a minor
role for clearance of intracellular pathogens during infection
but may be essential for immune down-modulation during the
chronic phases of inflammation, which is critical for reduced
intensity of tissue injury and organ dysfunction. For instance,
IL-27RA/ mice infected with T. gondii were still capable of
developing a protective T cell response and control of parasite
replication [21]. However, infected IL-27RA/ mice failed
to silence these protective responses, and mice consecutively
developed a lethal, T cell-mediated inflammation, including
exuberant IFN- production and T cell proliferation [21]. This
is, in part, contradictory to earlier findings of IL-27 synergizing
with IL-12 to induce IFN- from naive CD4 cells [1]. Follow-
ing protozoan infection with T. cruzi, IL-27RA/ mice dis-
played prolonged parasitemia, severe liver injury, and in-
creased mortality compared with WT mice [38]. Splenocytes
from IL-27RA/ mice secreted enhanced levels of Th2 cyto-
kines, as well as enhanced IFN-, IL-6, and TNF- production
in liver [38].
It is well established that IL-27 can act with anti-inflamma-
tory function via induction of IL-10 from various T cell sub-
sets, including Tregs [49]. IL-27 used the transcription factors
STAT1 and STAT3 to induce IL-10 in Th1, Th2, and Th17
cells [34]. In another study, IL-27-mediated gene expression of
IL-10 in IFN- Foxp3-Th1 cells, via STAT1 and IL-27RA/
mice, displayed fewer IL-10 T cells after L. monocytogenes in-
fection or EAE [37]. Likewise, IL-27 regulated IL-10 produc-
tion by CD4 cells following infection with Leishmania major
[50]. Mechanistically, IL-27 appears to induce the transcrip-
tion factor AhR, which partners with c-Maf to transactivate the
IL-10 gene promoter region, at least in Tregs (Tr1) [13]. Ad-
ditional transcription factors involved in IL-27-mediated ex-
pression of IL-10 have been identified as Egr-2 and B lympho-
cyte-induced maturation protein-1 [51]. IL-27 failed to induce
IL-10 in CD4 T cells derived from Egr-2/ mice [51]. The
loss of gp130 expression on CD8 memory cells was associated
with limited IL-27 responsiveness and diminished IL-10 pro-
duction during antigen rechallenge [52].
It is worth mentioning that several anti-inflammatory effects
of IL-27 are independent of IL-10, such as IL-27-mediated sup-
pression of Th17 cells during EAE [53]. In addition, IL-27
blocks the pathway for Th9 cell differentiation when added to
cultures of naive Th0 cells and also abrogates the encephalito-
genic potential of Th9 cells during EAE [54].
Whereas the nature of IL-27 effects on Th1 cell responses
(and IFN-) may vary in the context of different diseases,
there is clear evidence that IL-27 is a suppressor of Th2 and
Th17 cells [11, 38, 49]. IL-27 promotes a population of Tregs
(T-betCXCR3) with distinct transcriptional activation pro-
files compared with Tregs induced by IFN- [55]. In Tr1 cells,
metallothioneins appear to act as natural antagonists of IL-27
[56]. For example, in Tr1 cells from metallothionein-deficient
mice, IL-27 mediated more abundant STAT1/STAT3 phosphory-
lation, resulting in higher IL-10 production, together with more
efficient suppression of effector T cell proliferation [56].
Findings in several other studies have suggested anti-inflam-
matory properties of IL-27. IL-27RA/ mice were highly sus-
ceptible in the recovery phases following Plasmodium berghei
infection, and IL-27RA/ mice developed exuberant CD4
Th1 cell-associated liver pathology in an IL-10-resistant manner
[57]. IL-27A signaling, during experimental malaria infection,
suppressed the development of killer cell-like receptor group
1-expressing, terminally differentiated Th1 cells by desensitiz-
ing these cells to the effects of IL-12 and IL-2 [58]. CD4 T
cells from spleen expressed higher numbers of the CCR5 re-
ceptor (ligands: CCL4, CCL5) when genetically deficient of
IL-27RA [59]. This suggests that during malaria, infection
IL-27 restricts the chemotactic response of CD4 T cells, al-
though this appears to be contradictory to the findings that
IL-27 can induce CXCL10 (see above) [46].
In collagen-induced arthritis, using a bioengineered EBI3-L-
p28-Fc protein ameliorated joint inflammation, histology
scores, and release of IL-6, IL-17, and IFN- [36]. TNBS-in-
duced colitis was improved, including suppression of IL-17,
following administration of IL-27 [39]. In contrast to
EBI3/ mice [44], conditional CD11c-p28(flox/flox)/
mice were highly susceptible to Con A-induced liver injury
[60]. In keratinocytes and fibroblasts, IL-27 induced the pro-
duction of anti-inflammatory IL-18-binding protein, a natural
antagonist of IL-18 [61]. Finally, transgenic mice, overexpress-
ing p28 in T and B cells, were found to suppress IL-6R signal-
ing by direct interaction of p28 with the gp130R chain [5].
IMPLICATIONS OF IL-27 DURING HUMAN
DISEASE
There is accumulating evidence suggesting various roles of
IL-27 during autoimmune diseases in humans. Elevated con-
centrations of IL-27 were found in synovial fluids but not
plasma of patients with rheumatoid arthritis [62]. Gene ex-
pression of p28 and EBI3 was elevated in colonic mucosa of
patients with active Crohn’s disease [63]. In patients with pso-
riasis, the serum concentrations of IL-27 were elevated com-
pared with healthy controls, correlating with disease severity
and release of IFN- [64]. It has been suggested that endoge-
nous release of IL-27 mediates the clinical response following
therapeutic administration of IFN- in patients with multiple
sclerosis [65]. IL-27 concentrations were also elevated in pa-
tients with moderate or severe aplastic anemia, correlating
with the release of IFN- [66]. SNPs, in the gene encoding for
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IL-27, have been associated with the incidence of several auto-
immune diseases, such as asthma [67], chronic obstructive pul-
monary disease [68], and inflammatory bowel diseases [68], all
studied in Asian populations. One of these SNPs (g.-964AG) is
located in the promoter region of p28 and may influence the
binding affinity of a yet-to-be-identified transcription factor [67].
IL-27 has been evaluated recently as a novel, diagnostic bio-
marker for bacterial infections [69], whereas production of
IL-27 appears to be suppressed during HIV infection [70].
However, a functional IL-27 response would likely be helpful
to control HIV replication [71]. IL-27 was found recently to
confer resistance of macrophages to HIV by inhibiting spectrin
 nonerythrocyte 1, a required host factor for HIV-1 infection
[72]. Furthermore, IL-27 induced the expression of novel
microRNAs (miR-SX1, -SX2, -SX3, and -SX6) in human macro-
phages, which antivirally target the open reading frames of a
number of viruses (HSV-1, HSV-2, and HHV-8) [73]. On the
other hand, whereas infections with hepatitis B virus mediate
the release of IL-27 [74], quantification of IL-27 may not be
useful in determining pathologic stages and progression of
liver disease [75]. In addition, IL-27 in serum was elevated sig-
nificantly in patients with seasonal H1N1 virus subtype (H3N2)
or the 2009 pandemic H1N1 infection [76].
CONCLUDING REMARKS
During the past decade, our knowledge of the biology of IL-27
has evolved considerably. Accumulating literature indicates the
potential of IL-27 as an essential regulator of adaptive immu-
nity, most notably for T cell functions. One hallmark of IL-27
research was to identify its capability to induce anti-inflamma-
tory IL-10 from various T cell subsets via STAT1/STAT3 path-
ways. However, the versatile properties of IL-27 as an enhancer
or silencer of inflammation are still incompletely understood.
Recently, the involvement of the complement systems as a spe-
cific regulator of IL-27 production has added a new facet to
the puzzling picture of IL-27 biology. Conflicting data for IL-
27, promoting or antagonizing inflammation, may, in part, be
explained by differences in the disease models, transgenic
mouse strains, or bioengineered IL-27/IL-27RA proteins. Fu-
ture scientific efforts will need to analyze further the molecu-
lar mechanisms involved in expression and biological activity
of IL-27 in different cell types and models of disease.
To identify potential therapeutic approaches of targeting
IL-27 in humans with infectious or autoimmune diseases will
be important. Nevertheless, the complex roles of IL-27 may
complicate the search for effective therapeutic exploitation of
the IL-27 system. One risk, shared by many immunomodula-
tory pharmaceuticals, may be that manipulation of IL-27 dur-
ing autoimmune diseases may increase the occurrence of in-
fections or even malignancies. Moreover, it is currently not
entirely clear if IL-27 administration should be favored over a
blockade of IL-27 in certain autoimmune diseases, such as
rheumatoid arthritis. In the future, another potential area of
interest may be to evaluate further the roles of IL-27 in cardio-
vascular diseases and tumor biology. Any therapeutic interven-
tions regarding IL-27 and IL-27RA will require a careful medi-
cal evaluation before clinical studies can be considered.
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